Ocular Hypotensive Medications: Adherence and Performance

Gary D. Novack, Kelly W. Muir, Paula Anne Newman-Casey, Alan L. Robin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Glaucoma is a leading cause of blindness world-wide and first-line therapy is typically ocular hypotensive medications. Several large, multicenter trials have demonstrated that lowering intraocular pressure medically reduces the risk of glaucomatous visual field loss. However, the proportion of patients who inadequately comply with glaucoma medical therapy as prescribed ranges from 5% to 80%. In addition, instillation of eyedrops is challenging for many patients, adding another component to inadequate patient-delivered therapy. Patients who have poor understanding of the impact of glaucoma on vision are less likely to take their glaucoma drops properly. Poor adherence is associated with worse outcomes in glaucoma patients: worse visual field defects, and greater fluctuation in intraocular pressure (IOP), which also may contribute to worsening disease. Therapeutics might be enhanced by education of both the importance of medication use, and simply how to take eye drops. The financial impact of inadequate patient-delivery therapy is discussed, as are some simple proposals for improving therapeutics.

Original languageEnglish (US)
Title of host publicationMedical Diagnosis and Therapy
PublisherElsevier Inc.
Pages521-524
Number of pages4
Volume1
ISBN (Print)9780702055416, 9780702051937
DOIs
StatePublished - Sep 3 2014

Fingerprint

Medication Adherence
Glaucoma
Ophthalmic Solutions
Visual Fields
Intraocular Pressure
Therapeutics
Blindness
Multicenter Studies
Education

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Novack, G. D., Muir, K. W., Newman-Casey, P. A., & Robin, A. L. (2014). Ocular Hypotensive Medications: Adherence and Performance. In Medical Diagnosis and Therapy (Vol. 1, pp. 521-524). Elsevier Inc.. https://doi.org/10.1016/B978-0-7020-5193-7.00049-2

Ocular Hypotensive Medications : Adherence and Performance. / Novack, Gary D.; Muir, Kelly W.; Newman-Casey, Paula Anne; Robin, Alan L.

Medical Diagnosis and Therapy. Vol. 1 Elsevier Inc., 2014. p. 521-524.

Research output: Chapter in Book/Report/Conference proceedingChapter

Novack, GD, Muir, KW, Newman-Casey, PA & Robin, AL 2014, Ocular Hypotensive Medications: Adherence and Performance. in Medical Diagnosis and Therapy. vol. 1, Elsevier Inc., pp. 521-524. https://doi.org/10.1016/B978-0-7020-5193-7.00049-2
Novack GD, Muir KW, Newman-Casey PA, Robin AL. Ocular Hypotensive Medications: Adherence and Performance. In Medical Diagnosis and Therapy. Vol. 1. Elsevier Inc. 2014. p. 521-524 https://doi.org/10.1016/B978-0-7020-5193-7.00049-2
Novack, Gary D. ; Muir, Kelly W. ; Newman-Casey, Paula Anne ; Robin, Alan L. / Ocular Hypotensive Medications : Adherence and Performance. Medical Diagnosis and Therapy. Vol. 1 Elsevier Inc., 2014. pp. 521-524
@inbook{39dfef8a49874780832ab8dfa7012515,
title = "Ocular Hypotensive Medications: Adherence and Performance",
abstract = "Glaucoma is a leading cause of blindness world-wide and first-line therapy is typically ocular hypotensive medications. Several large, multicenter trials have demonstrated that lowering intraocular pressure medically reduces the risk of glaucomatous visual field loss. However, the proportion of patients who inadequately comply with glaucoma medical therapy as prescribed ranges from 5{\%} to 80{\%}. In addition, instillation of eyedrops is challenging for many patients, adding another component to inadequate patient-delivered therapy. Patients who have poor understanding of the impact of glaucoma on vision are less likely to take their glaucoma drops properly. Poor adherence is associated with worse outcomes in glaucoma patients: worse visual field defects, and greater fluctuation in intraocular pressure (IOP), which also may contribute to worsening disease. Therapeutics might be enhanced by education of both the importance of medication use, and simply how to take eye drops. The financial impact of inadequate patient-delivery therapy is discussed, as are some simple proposals for improving therapeutics.",
author = "Novack, {Gary D.} and Muir, {Kelly W.} and Newman-Casey, {Paula Anne} and Robin, {Alan L.}",
year = "2014",
month = "9",
day = "3",
doi = "10.1016/B978-0-7020-5193-7.00049-2",
language = "English (US)",
isbn = "9780702055416",
volume = "1",
pages = "521--524",
booktitle = "Medical Diagnosis and Therapy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Ocular Hypotensive Medications

T2 - Adherence and Performance

AU - Novack, Gary D.

AU - Muir, Kelly W.

AU - Newman-Casey, Paula Anne

AU - Robin, Alan L.

PY - 2014/9/3

Y1 - 2014/9/3

N2 - Glaucoma is a leading cause of blindness world-wide and first-line therapy is typically ocular hypotensive medications. Several large, multicenter trials have demonstrated that lowering intraocular pressure medically reduces the risk of glaucomatous visual field loss. However, the proportion of patients who inadequately comply with glaucoma medical therapy as prescribed ranges from 5% to 80%. In addition, instillation of eyedrops is challenging for many patients, adding another component to inadequate patient-delivered therapy. Patients who have poor understanding of the impact of glaucoma on vision are less likely to take their glaucoma drops properly. Poor adherence is associated with worse outcomes in glaucoma patients: worse visual field defects, and greater fluctuation in intraocular pressure (IOP), which also may contribute to worsening disease. Therapeutics might be enhanced by education of both the importance of medication use, and simply how to take eye drops. The financial impact of inadequate patient-delivery therapy is discussed, as are some simple proposals for improving therapeutics.

AB - Glaucoma is a leading cause of blindness world-wide and first-line therapy is typically ocular hypotensive medications. Several large, multicenter trials have demonstrated that lowering intraocular pressure medically reduces the risk of glaucomatous visual field loss. However, the proportion of patients who inadequately comply with glaucoma medical therapy as prescribed ranges from 5% to 80%. In addition, instillation of eyedrops is challenging for many patients, adding another component to inadequate patient-delivered therapy. Patients who have poor understanding of the impact of glaucoma on vision are less likely to take their glaucoma drops properly. Poor adherence is associated with worse outcomes in glaucoma patients: worse visual field defects, and greater fluctuation in intraocular pressure (IOP), which also may contribute to worsening disease. Therapeutics might be enhanced by education of both the importance of medication use, and simply how to take eye drops. The financial impact of inadequate patient-delivery therapy is discussed, as are some simple proposals for improving therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84944402890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944402890&partnerID=8YFLogxK

U2 - 10.1016/B978-0-7020-5193-7.00049-2

DO - 10.1016/B978-0-7020-5193-7.00049-2

M3 - Chapter

AN - SCOPUS:84944402890

SN - 9780702055416

SN - 9780702051937

VL - 1

SP - 521

EP - 524

BT - Medical Diagnosis and Therapy

PB - Elsevier Inc.

ER -